Anker SD, Khan MS, Butler J, Ofstad AP, Peil B, Pfarr E, Doehner W, Sattar N, Coats AJS, Filippatos G, Ferreira JP, Zannad F, Pocock S, Packer M (2023) Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced. Eur J Heart Fail 25:117–127. https://doi.org/10.1002/ejhf.2728

Article  CAS  PubMed  Google Scholar 

Baartscheer A, Hardziyenka M, Schumacher CA, Belterman CN, van Borren MM, Verkerk AO, Coronel R, Fiolet JW (2008) Chronic inhibition of the Na+/H+ - exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling. Br J Pharmacol 154:1266–1275. https://doi.org/10.1038/bjp.2008.189

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baartscheer A, Schumacher CA, van Borren MM, Belterman CN, Coronel R, Fiolet JW (2003) Increased Na+/H+-exchange activity is the cause of increased [Na+]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res 57:1015–1024. https://doi.org/10.1016/s0008-6363(02)00809-x

Article  CAS  PubMed  Google Scholar 

Baartscheer A, Schumacher CA, Wust RC, Fiolet JW, Stienen GJ, Coronel R, Zuurbier CJ (2017) Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)/H(+) exchanger in rats and rabbits. Diabetologia 60:568–573. https://doi.org/10.1007/s00125-016-4134-x

Article  CAS  PubMed  Google Scholar 

Bay J, Kohlhaas M, Maack C (2013) Intracellular Na(+) and cardiac metabolism. J Mol Cell Cardiol 61:20–27. https://doi.org/10.1016/j.yjmcc.2013.05.010

Article  CAS  PubMed  Google Scholar 

Belge C, Hammond J, Dubois-Deruy E, Manoury B, Hamelet J, Beauloye C, Markl A, Pouleur AC, Bertrand L, Esfahani H, Jnaoui K, Gotz KR, Nikolaev VO, Vanderper A, Herijgers P, Lobysheva I, Iaccarino G, Hilfiker-Kleiner D, Tavernier G, Langin D, Dessy C, Balligand JL (2014) Enhanced expression of beta3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. Circulation 129:451–462. https://doi.org/10.1161/CIRCULATIONAHA.113.004940

Article  CAS  PubMed  Google Scholar 

Billing AM, Kim YC, Gullaksen S, Schrage B, Raabe J, Hutzfeldt A, Demir F, Kovalenko E, Lasse M, Dugourd A, Fallegger R, Klampe B, Jaegers J, Li Q, Kravtsova O, Crespo-Masip M, Palermo A, Fenton RA, Hoxha E, Blankenberg S, Kirchhof P, Huber TB, Laugesen E, Zeller T, Chrysopoulou M, Saez-Rodriguez J, Magnussen C, Eschenhagen T, Staruschenko A, Siuzdak G, Poulsen PL, Schwab C, Cuello F, Vallon V, Rinschen MM (2024) Metabolic communication by SGLT2 inhibition. Circulation 149:860–884. https://doi.org/10.1161/CIRCULATIONAHA.123.065517

Article  CAS  PubMed  Google Scholar 

Borges-Junior FA, Silva Dos Santos D, Benetti A, Polidoro JZ, Wisnivesky ACT, Crajoinas RO, Antonio EL, Jensen L, Caramelli B, Malnic G, Tucci PJ, Girardi ACC (2021) Empagliflozin inhibits proximal tubule NHE3 activity, preserves GFR, and restores euvolemia in nondiabetic rats with induced heart failure. J Am Soc Nephrol 32:1616–1629. https://doi.org/10.1681/ASN.2020071029

Article  PubMed  PubMed Central  Google Scholar 

Capone F, Vettor R, Schiattarella GG (2023) Cardiometabolic HFpEF: NASH of the heart. Circulation 147:451–453. https://doi.org/10.1161/CIRCULATIONAHA.122.062874

Article  PubMed  Google Scholar 

Cappetta D, De Angelis A, Ciuffreda LP, Coppini R, Cozzolino A, Micciche A, Dell’Aversana C, D’Amario D, Cianflone E, Scavone C, Santini L, Palandri C, Naviglio S, Crea F, Rota M, Altucci L, Rossi F, Capuano A, Urbanek K, Berrino L (2020) Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium. Pharmacol Res 157:104781. https://doi.org/10.1016/j.phrs.2020.104781

Article  CAS  PubMed  Google Scholar 

Chen S, Coronel R, Hollmann MW, Weber NC, Zuurbier CJ (2022) Direct cardiac effects of SGLT2 inhibitors. Cardiovasc Diabetol 21:45. https://doi.org/10.1186/s12933-022-01480-1

Article  CAS  PubMed  Google Scholar 

Chen S, Overberg K, Ghouse Z, Hollmann MW, Weber NC, Coronel R, Zuurbier CJ (2024) Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition. Biomed Pharmacother 174:116477. https://doi.org/10.1016/j.biopha.2024.116477

Article  CAS  PubMed  Google Scholar 

Chen S, Schumacher CA, Van Amersfoorth SCM, Fiolet JWT, Baartscheer A, Veldkamp MW, Coronel R, Zuurbier CJ (2023) Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells. Front Physiol 14:1179131. https://doi.org/10.3389/fphys.2023.1179131

Article  PubMed  Google Scholar 

Chen S, Wang Q, Christodoulou A, Mylonas N, Bakker D, Nederlof R, Hollmann MW, Weber NC, Coronel R, Wakker V, Christoffels VM, Andreadou I, Zuurbier CJ (2023) Sodium glucose cotransporter-2 inhibitor empagliflozin reduces infarct size independently of sodium glucose cotransporter-2. Circulation 147:276–279. https://doi.org/10.1161/CIRCULATIONAHA.122.061688

Article  CAS  PubMed  Google Scholar 

Choi J, Matoba N, Setoyama D, Watanabe D, Ohnishi Y, Yasui R, Kitai Y, Oomachi A, Kotobuki Y, Nishiya Y, Pieper MP, Imamura H, Yanagita M, Yamamoto M (2023) The SGLT2 inhibitor empagliflozin improves cardiac energy status via mitochondrial ATP production in diabetic mice. Commun Biol 6:278. https://doi.org/10.1038/s42003-023-04663-y

Article  CAS  PubMed  Google Scholar 

Christ T, Schwedhelm E, Eschenhagen T (2024) Dapagliflozin and atrial fibrillation: elevated dosing to achieve class I antiarrhythmic effects? Basic Res Cardiol 119:505–507. https://doi.org/10.1007/s00395-024-01047-z

Article  PubMed  Google Scholar 

Chung YJ, Park KC, Tokar S, Eykyn TR, Fuller W, Pavlovic D, Swietach P, Shattock MJ (2021) Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart. Cardiovasc Res 117:2794–2806. https://doi.org/10.1093/cvr/cvaa323

Article  CAS  PubMed  Google Scholar 

Dyck JRB, Sossalla S, Hamdani N, Coronel R, Weber NC, Light PE, Zuurbier CJ (2022) Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: evidence for potential off-target effects. J Mol Cell Cardiol 167:17–31. https://doi.org/10.1016/j.yjmcc.2022.03.005

Article  CAS  PubMed  Google Scholar 

Engelhardt S, Hein L, Keller U, Klambt K, Lohse MJ (2002) Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice. Circ Res 90:814–819. https://doi.org/10.1161/01.res.0000014966.97486.c0

Article  CAS  PubMed  Google Scholar 

Ferdinandy P, Andreadou I, Baxter GF, Bøtker HE, Davidson SM, Dobrev D, Gersh BJ, Heusch G, Lecour S, Ruiz-Meana M, Zuurbier CJ, Hausenloy DJ, Schulz R (2023) Interaction of cardiovascular nonmodifiable risk factors, comorbidities and comedications with ischemia/reperfusion injury and cardioprotection by pharmacological treatments and ischemic conditioning. Pharmacol Rev 75:159–216. https://doi.org/10.1124/pharmrev.121.000348

Article  CAS  PubMed  Google Scholar 

Ferdinandy P, Baczkó I, Bencsik P, Giricz Z, Görbe A, Pacher P, Varga ZV, Varró A, Schulz R (2019) Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications. Eur Heart J 40:1771–1777. https://doi.org/10.1093/eurheartj/ehy365

Article  CAS  PubMed  Google Scholar 

Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R (2000) Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 87:241–247. https://doi.org/10.1161/01.res.87.3.241

Article  CAS  PubMed  Google Scholar 

Ferrannini E, Mark M, Mayoux E (2016) CV protection in the EMPA-REG OUTCOME trial: a “thrifty substrate” hypothesis. Diabetes Care 39:1108–1114. https://doi.org/10.2337/dc16-0330

Article  PubMed  Google Scholar 

Garciarena CD, Youm JB, Swietach P, Vaughan-Jones RD (2013) H(+)-activated Na(+) influx in the ventricular myocyte couples Ca(2)(+)-signalling to intracellular pH. J Mol Cell Cardiol 61:51–59. https://doi.org/10.1016/j.yjmcc.2013.04.008

Article  CAS  PubMed  Google Scholar 

Guo H, Yu X, Liu Y, Paik DT, Justesen JM, Chandy M, Jahng JWS, Zhang T, Wu W, Rwere F, Zhao SR, Pokhrel S, Shivnaraine RV, Mukherjee S, Simon DJ, Manhas A, Zhang A, Chen CH, Rivas MA, Gross ER, Mochly-Rosen D, Wu JC (2023) SGLT2 inhibitor ameliorates endothelial dysfunction associated with the common ALDH2 alcohol flushing variant. Sci Transl Med 15:eabp9952. https://doi.org/10.1126/scitranslmed.abp9952

Article  CAS  PubMed